KD-4001 is under clinical development by Kyung Dong and currently in Phase I for Diabetes. According to GlobalData, Phase I drugs for Diabetes have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KD-4001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KD-4001 overview
KD-4001 is under development for the treatment of diabetes. The drug candidate is an incrementally modified drug (IMD). It is administered through oral route as a tablet.
Kyung Dong overview
Kyung Dong is engaged in coal mining. It offers mining and general, power plants, public projects, domestic resource development and overseas resource development services. Kyung Dong is headquartered in Siheung-si, Gyeonggi-do, South Korea.
For a complete picture of KD-4001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
